Cue Biopharma, a clinical-stage biopharmaceutical company, announced a $50 million private placement by selling 1.4 million shares and pre-funded warrants to accredited investors at about $33.21 per share. The funding, led by Cormorant Asset Management and including Columbia Threadneedle Investments, will support Cue's clinical development and general corporate needs. The company is advancing therapies targeting functional cures for immunological disorders, with upcoming clinical data expected by Q3 2026. The private placement is expected to close around July 13, 2026, subject to customary conditions.
Shell plc completed a $16.5 billion acquisition of ARC Resources Ltd., boosting its production by 370,000 barrels of oil equivalent per day and targeting 4% annual growth through 2030. The company also agreed to acquire the remaining 67% of Tri Star ...
Teladoc Health's BetterHelp segment saw an 11.6% revenue drop and a near-zero profit margin in Q2 2026, partly due to a shift from cash to insurance payments. The company lowered its full-year 2026 revenue guidance to $2.36-$2.45 billion from $2.48-$...
Zscaler reported strong fiscal Q4 results, surpassing analyst expectations with an EPS of $1.19 and revenue of $898.19 million, a 25% year-over-year growth. The company credits its robust performance to strategic investments in artificial intelligenc...
Crusoe, a data center developer serving clients like Meta, Microsoft, and OpenAI, raised $3 billion at a $30 billion valuation. The funding round was co-led by Atreides Management and Valor Equity Partners, with Mubadala Capital also participating. C...
The memecoin creation app Pons generated $5.95 million in fees within 24 hours on Robinhood's blockchain, making it the fourth-largest protocol by daily fees globally. Users launched nearly 25,000 new tokens in one day, pushing trading volume to $544...
